UBS AM
LENZ

UBS AM’s LENZ Therapeutics LENZ Stock Holding History

UBS AM’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$812 Sell
143
-25,645
-99% -$207K ﹤0.01% 3632
2026
Q1 		$236K Buy
25,788
+6,937
+37% +$97.5K ﹤0.01% 2702
2025
Q4 		$302K Buy
18,851
+7,154
+61% +$209K ﹤0.01% 2413
2025
Q3 		$545K Sell
11,697
-13,458
-54% -$495K ﹤0.01% 2142
2025
Q2 		$737K Buy
+25,155
New +$684K ﹤0.01% 2442
2022
Q2 		– Sell
-34,493
Closed -$1.23M – 2783
2022
Q1 		$1.23M Sell
34,493
-2,182
-6% -$137K ﹤0.01% 2025
2021
Q4 		$3.19M Sell
36,675
-26,568
-42% -$2.2M ﹤0.01% 1636
2021
Q3 		$7.26M Buy
63,243
+6,988
+12% +$1.03M ﹤0.01% 1216
2021
Q2 		$12.1M Buy
+56,255
New +$9.8M 0.01% 1053

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

UBS AM's LENZ Position: Q2 2026 in Review

UBS AM reduced its LENZ Therapeutics (LENZ) stake by 99% in Q2 2026, selling an estimated $207K and leaving 143 shares worth $812. The position accounts for ﹤0.01% of the portfolio, ranked #3632.

UBS AM first reported a position in LENZ in Q2 2021 and has held it in 9 quarters since. The position peaked at $12.1M in Q2 2021. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • UBS AM held 143 shares of LENZ Therapeutics worth $812 as of Q2 2026.
  • UBS AM sold 25,645 LENZ Therapeutics shares in Q2 2026, an estimated $207K.
  • LENZ Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3632 holding.
  • UBS AM first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • UBS AM's LENZ Therapeutics position peaked at $12.1M in Q2 2021.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.